Pomerantz LLP Investigates Iovance Biotherapeutics for Potential Securities Claims
Law firm Pomerantz LLP has launched an investigation into Iovance Biotherapeutics regarding potential securities fraud or unlawful business practices.
Stocks · News reference
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citizens Maintains Iovance Biotherapeutics at Market Outperform and Raises Price Target
Citizens has maintained its 'Market Outperform' rating on Iovance Biotherapeutics and increased its price target from $8 to $12.
IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline Progress
Iovance Biotherapeutics (IOVA) reported Q3 2026 revenues of $121.5M, surpassing estimates, with Amtagvi sales growing 77% to $102M. The company reaffirmed full-year revenue guidance of $410-$420M, highlighted improving gross margins at 60%, and advanced its pipeline with lung cancer and sarcoma trials targeting regulatory submissions in 2027-2029. Management expects cash resources to support operations into 2029.
8-K filing — IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
Filed: 2026-11-05 AccNo: 0001193125-26-450084 Size: 19 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Iovance Biotherapeutics Q3 2026 Earnings Call Transcript
Iovance Biotherapeutics (NASDAQ:IOVA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by
Iovance Biotherapeutics Reports Third Quarter 2026 Financial Results
Iovance Biotherapeutics announced its financial results for the third quarter of 2026, reporting record revenue of approximately $122 million.